Glenmark receives approval for oral antiviral Favipiravir for the treatment of mild to moderate COVID-19






In a landmark improvement for COVID-19 sufferers in India, Glenmark Pharmaceuticals bought approval of antiviral drug Favipiravir (model title FabiFlu®) for the treatment of mild to moderate COVID-19 sufferers. Glenmark has obtained manufacturing and advertising approval from India’s drug regulator, making FabiFlu® the first oral Favipiravir-approved remedy in India for the treatment of COVID-19.

Favipiravir is backed by sturdy medical proof displaying encouraging ends in sufferers with mild to moderate COVID-19. The antiviral affords broad spectrum RNA virus protection with medical enchancment famous throughout age teams 20 to >90 years. Favipiravir can be utilized in COVID-19 sufferers with co-morbid circumstances resembling diabetes and coronary heart diseasewith mild to moderate COVID 19 signs. It affords fast discount in viral load inside four days and gives quicker symptomatic and radiological enchancment.Of most significance, Favipiravir has proven medical improvementof up to 88% in COVID-19 mild to moderate COVID 19 circumstances.

Glenmark efficiently developed the lively pharmaceutical ingredient (API) and the formulation for FabiFlu® by way of its personal in-house R&D workforce.Glenmark filed the product for medical trial with India’s drug regulator DCGI and have become the first pharmaceutical firm in India to obtain approval for conducting section three medical trial on mild to moderate COVID-19 sufferers.

Commenting on the significance of this improvement, Mr. Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals Ltd., mentioned, “This approval comes at a time when cases in India are spiralling like never before,putting a tremendous pressure on our healthcare system. We hope the availability of an effective treatment such as FabiFlu® will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option.”

He added, “FabiFlu® has demonstrated an encouraging response in mild to moderate COVID-19 patients during clinical trials. Moreover, it is orally administered, and so it serves as a more convenient treatment option over other intravenously administered medications. Glenmark will work closely with the government and medical community to make FabiFlu® quickly accessible to patients across the country.”

Favipiravir is authorised in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It has a novel mechanism of motion: it’s transformed into an lively phosphoribosylated kind (favipiravir-RTP) in cells and acknowledged as a substrate by viral RNA polymerase, thereby inhibiting RNA polymerase exercise.

Most sufferers exhibiting mild to moderate signs can profit from FabiFlu® use.The drug will probably be out there as a prescription-based medicationfor INR 103/pill,with beneficial dose being1800 mg twice day by day on day 1, adopted by 800 mg twice day by day up to day 14.

Earlier final month, Glenmark additionally introduced that it’s conducting one other medical trial to consider the efficacy of two antivirals Favipiravir and Umifenovir as a mixture remedy in moderate hospitalized grownup COVID-19 sufferers in India.